MARKET

SGEN

SGEN

Seattle Genetics
NASDAQ

Real-time Quotes | Nasdaq Last Sale

158.79
+5.31
+3.46%
Closed 19:50 08/12 EDT
OPEN
153.93
PREV CLOSE
153.48
HIGH
158.89
LOW
153.69
VOLUME
730.12K
TURNOVER
--
52 WEEK HIGH
187.99
52 WEEK LOW
65.44
MARKET CAP
27.63B
P/E (TTM)
-106.1714
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 19 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average SGEN stock price target is 179.82 with a high estimate of 253.00 and a low estimate of 130.00.

EPS

SGEN News

More
Seattle Genetics shares are trading higher after the company announced TUKYSA was approved for all countries participating in FDA's Project Orbis initiative.
Benzinga · 14h ago
Seattle Genetics Announces TUKYSA Approved For All Countries Participating In FDA's Project Orbis Initiative
- Australia Joins U.S., Switzerland, Canada and Singapore in Approval of TUKYSA for the Treatment of Patients with Locally Advanced or Metastatic HER2-Positive Breast Cancer - Seattle Genetics, Inc. (NASDAQ:SGEN)
Australia Joins U.S., Switzerland, Canada and Singapore in Approval of TUKYSA for the Treatment of Patients with Locally Advanced or Metastatic HER2-Positive Breast Cancer - Seattle Genetics, Inc. (NASDAQ:SGEN) · 21h ago
FDA OKs Glaxo antibody-drug conjugate for last-line multiple myeloma
The FDA approves GlaxoSmithKline's (NYSE:GSK) Blenrep (belantamab mafodotin-blmf) for the treatment of adults with relapsed/refractory multiple myeloma (MM
seekingalpha · 6d ago
Seattle Genetics Achieves Milestone Payment Under Antibody-Drug Conjugate Collaboration with GlaxoSmithKline Triggered by BLENREP (belantamab mafodotin-blmf) FDA Approval
Seattle Genetics, Inc. (Nasdaq:SGEN) today announced U.S. Food and Drug Administration (FDA) approval of GlaxoSmithKline’s (GSK) BLENREP™ (belantamab mafodotin-blmf), an antibody-drug conjugate (ADC) targeting B-cell maturation antigen (BCMA) that utilizes Sea
Business Wire · 6d ago
Seattle Genetics (SGEN) Q2 Earnings Beat, Adcetris Aids Sales
Seattle Genetics (SGEN) reports a narrower-than-expected loss and beats sales estimates in the second quarter of 2020.
Zacks · 07/31 15:16
Wall Street Breakfast: Big Beats From Big Tech
Seeking Alpha · 07/31 11:04
Seattle Genetics, Inc. (SGEN) CEO Clay Siegall on Q2 2020 Results - Earnings Call Transcript
Seeking Alpha · 07/31 10:58
Seattle Genetics EPS beats by $0.48, beats on revenue
Seattle Genetics (NASDAQ:SGEN): Q2 GAAP EPS of -$0.12 beats by $0.48. Revenue of $278M (+27.3% Y/Y) beats by $21.08M. Adcetris of $167.5M misses consensus
seekingalpha · 07/31 01:17

Industry

Biotechnology & Medical Research
+0.80%
Pharmaceuticals & Medical Research
+1.79%

Hot Stocks

Symbol
Price
%Change

About SGEN

Seattle Genetics, Inc. is a biotechnology company focused on the development and commercialization of therapies for the treatment of cancer. The Company is engaged in the development and sale of pharmaceutical products on its own behalf or in collaboration with others. The Company's marketed product ADCETRIS, or brentuximab vedotin, is an antibody-drug conjugate (ADC). In addition to ADCETRIS, the Company's pipeline includes other clinical-stage ADC programs, such as ASG-22ME, SGN-LIV1A, SGN-CD19A, SGN-CD19B, SGN-CD123A, SGN-352A, and ASG-15ME, as well as two immuno-oncology agents, SEA-CD40, which is based on its sugar-engineered antibody (SEA) technology, and SGN-2FF, which is a small molecule. It also has multiple preclinical and research-stage programs that employ its technologies, including SGN-CD48A and a preclinical ADC. ADCETRIS is an ADC comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent.
More

Webull offers kinds of Seattle Genetics, Inc. stock information, including NASDAQ:SGEN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SGEN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SGEN stock methods without spending real money on the virtual paper trading platform.